Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MOG-Peptide Synergizes With Rapamycin to Drive CD4<sup>+</sup> T Cells Into Protective Antigen-Specific Tregs in EAE.

Immunology·2026
Same author

Morphine disrupts antigen-presenting cell function through TLR-4 and autophagy pathways.

Molecular biology reports·2026
Same author

Mental health strain due to COVID-19: Psychological distress and somatic symptoms among health care workers and the general population in Kashmir, India.

Virus research·2026
Same author

Morphine Dependence Vaccines: Advances, Challenges, and Future Directions.

Current pharmaceutical biotechnology·2026
Same author

Lactobacillus plantarum as a Novel Modulator of Immune and Behavioral Recovery in Substance Use Disorders: A Hypothesis.

Current drug research reviews·2026
Same author

Recent advances in drug repurposing for cancer immunomodulation emerging strategies, mechanistic insights, and clinical translation.

Frontiers in oncology·2026
Same journal

Mechanistic constraints in dengue severity: a systematic review with evidence stratification and agent-based evaluation of logical sufficiency.

Frontiers in immunology·2026
Same journal

Circadian control of immune homeostasis in cardiovascular health and disease.

Frontiers in immunology·2026
Same journal

An IHC-derived TLS-CD8-macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC.

Frontiers in immunology·2026
Same journal

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation.

Frontiers in immunology·2026
Same journal

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming.

Frontiers in immunology·2026
Same journal

A self-perpetuating neuron-intrinsic GSDMD-mtDNA-AIM2 inflammasome axis drives neuronal pyroptosis and cognitive impairment after traumatic brain injury.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Reprogramming dendritic cells to overcome tumor-mediated immune suppression.

Jonaid Ahmad Malik1

  • 1Department of Biomedical Engineering, Indian Institute of Technology, Ropar, India.

Frontiers in Immunology
|July 2, 2026
PubMed
Summary
This summary is machine-generated.

Dendritic cells (DCs) are crucial for anti-cancer immunity but become dysfunctional in tumors. This review explores how to restore their function using novel reprogramming strategies for better cancer immunotherapy.

Keywords:
dendritic cellsdysfunctionimmunotherapynovel mechanismsreprogrammingtumor microenvironment

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jul 3, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Dendritic cells (DCs) are key regulators of antitumor immunity.
  • Solid tumors often induce DC dysfunction, promoting immune evasion and cancer progression.
  • Novel roles of DC subsets in antigen processing and immune regulation are emerging.

Purpose of the Study:

  • To review mechanisms of DC impairment in the tumor microenvironment.
  • To highlight innovative strategies for reprogramming dysfunctional DCs.
  • To provide a framework for enhancing DC-based cancer immunotherapy.

Main Methods:

  • Review of recent literature on DC biology in cancer.
  • Analysis of mechanisms driving DC dysfunction (epigenetic, metabolic, suppressive networks).
  • Discussion of therapeutic strategies targeting DCs.

Main Results:

  • DC dysfunction is driven by epigenetic reprogramming, metabolic changes, and tumor-derived factors.
  • Strategies like transcription factor modulation and nanoparticle-based antigen delivery can reprogram DCs.
  • Inducing DC-like phenotypes from other cells is a potential therapeutic avenue.

Conclusions:

  • Restoring DC immunogenicity is critical for effective cancer immunotherapy.
  • Integrating mechanistic insights with translational innovations offers promising therapeutic avenues.
  • Targeting DC dysfunction can enhance antitumor immunity and combat cancer progression.